Immunome (IMNM) Cash from Operations Growth (1y) (2020 - 2026)

Immunome (IMNM) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 356.73%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.23%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Immunome 2.51 Bn 1.93 Bn - -10.52%

Historic Data

Download Data
DateValue
Mar 31, 2026 -10.52%
Dec 31, 2025 -14.01%
Sep 30, 2025 -18.56%
Jun 30, 2025 -111.14%
Mar 31, 2025 -374.98%
Dec 31, 2024 -140.91%
Sep 30, 2024 -296.64%
Jun 30, 2024 -312.79%
Mar 31, 2024 -146.21%
Dec 31, 2023 -161.24%
Sep 30, 2023 -13.78%
Jun 30, 2023 29.68%
Mar 31, 2023 479.12%
Dec 31, 2022 1.79%
Sep 30, 2022 -82.65%
Jun 30, 2022 -115.45%
Mar 31, 2022 -80.37%
Dec 31, 2021 -12.26%
Sep 30, 2021 -63.96%
Jun 30, 2021 -152.77%